Literature DB >> 16886597

Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer.

Margit Maria Janát-Amsbury1, James William Yockman, Matthew Linley Anderson, Dirk Günter Kieback, Sung Wan Kim.   

Abstract

Attempts to develop novel immunotherapeutic mouse models have been hampered by the lack of an adequate in vivo system. This study was performed to establish an immunocompetent mouse model for the testing of immunotherapy concepts. The in vivo system was based on a svngeneic mouse ovarian surface epithelium (MOSE) cancer, physiologically and biologically closely resembling human epithelial ovarian cancer. In addition, a more aggressive variant containing a mutated form of vascular epithelial growth factor was also evaluated. The growth patterns of these ovarian cancer cells in mice were compared to the established, highly aggressive 4T1 breast cancer model. A clinically-relevant tool for the study of different growth patterns in ovarian cancer, with potential significance for the development of novel immunological methods, was successfully developed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886597

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

1.  Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors:  Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal:  J Control Release       Date:  2019-05-17       Impact factor: 9.776

2.  Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.

Authors:  Meredith L Stone; Katherine B Chiappinelli; Huili Li; Lauren M Murphy; Meghan E Travers; Michael J Topper; Dimitrios Mathios; Michael Lim; Ie-Ming Shih; Tian-Li Wang; Chien-Fu Hung; Vipul Bhargava; Karla R Wiehagen; Glenn S Cowley; Kurtis E Bachman; Reiner Strick; Pamela L Strissel; Stephen B Baylin; Cynthia A Zahnow
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

3.  Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.

Authors:  Neha N Parayath; Srujan Kumar Gandham; Fraser Leslie; Mansoor M Amiji
Journal:  Cancer Lett       Date:  2019-07-06       Impact factor: 8.679

4.  Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.

Authors:  Kristin G Anderson; Valentin Voillet; Breanna M Bates; Edison Y Chiu; Madison G Burnett; Nicolas M Garcia; Shannon K Oda; Christopher B Morse; Ingunn M Stromnes; Charles W Drescher; Raphael Gottardo; Philip D Greenberg
Journal:  Cancer Immunol Res       Date:  2019-07-23       Impact factor: 11.151

5.  CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.

Authors:  Margaret Gil; Marcin P Komorowski; Mukund Seshadri; Hanna Rokita; A J Robert McGray; Mateusz Opyrchal; Kunle O Odunsi; Danuta Kozbor
Journal:  J Immunol       Date:  2014-10-15       Impact factor: 5.422

6.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.

Authors:  K Abiko; N Matsumura; J Hamanishi; N Horikawa; R Murakami; K Yamaguchi; Y Yoshioka; T Baba; I Konishi; M Mandai
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

7.  Biopolymer implants enhance the efficacy of adoptive T-cell therapy.

Authors:  Sirkka B Stephan; Alexandria M Taber; Ilona Jileaeva; Ericka P Pegues; Charles L Sentman; Matthias T Stephan
Journal:  Nat Biotechnol       Date:  2014-12-15       Impact factor: 54.908

8.  Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.

Authors:  Marcin P Komorowski; Aj Robert McGray; Agnieszka Kolakowska; Kevin Eng; Margaret Gil; Mateusz Opyrchal; Bogumila Litwinska; Michael J Nemeth; Kunle O Odunsi; Danuta Kozbor
Journal:  Mol Ther Oncolytics       Date:  2016-12-14       Impact factor: 7.200

9.  Ovarian cancer mouse models: a summary of current models and their limitations.

Authors:  Miranda Y Fong; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-09-28       Impact factor: 4.234

10.  Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.

Authors:  Sonia Iyer; Shuang Zhang; Simge Yucel; Heiko Horn; Sean G Smith; Ferenc Reinhardt; Esmee Hoefsmit; Bimarzhan Assatova; Julia Casado; Marie-Charlotte Meinsohn; M Inmaculada Barrasa; George W Bell; Fernando Pérez-Villatoro; Kaisa Huhtinen; Johanna Hynninen; Jaana Oikkonen; Pamoda M Galhenage; Shailja Pathania; Paula T Hammond; Benjamin G Neel; Anniina Farkkila; David Pépin; Robert A Weinberg
Journal:  Cancer Discov       Date:  2020-11-06       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.